PMDA drug package insert
レリフェン錠400mg
PMDA Prescription drug · 株式会社三和化学研究所 · package insert Mar 17, 2025
Key facts
| Brand names | レリフェン錠400mg |
|---|---|
| Nonproprietary names | ナブメトン |
| Companies | 製造販売元／株式会社三和化学研究所, 提携／グラクソ グループ リミテッド |
| Product type | Prescription drug |
| Therapeutic category | 持続性抗炎症・鎮痛剤 |
| Therapeutic category codes | 871149 |
| YJ codes | 1149027F1034 |
| Approval numbers | 21900AMX01336000 |
| Package insert edition | 第2版 |
| Package insert date | Mar 17, 2025 |
| PMDA document key | 300297_1149027F1034_1 |
| PMDA company code | 300297 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: